New York, April 15, 2024 - PRISM MarketView - IceCure Medical Ltd. (Nasdaq: ICCM) has submitted final data to the FDA requesting marketing authorization for ProSense® as a treatment for early stage T1 invasive breast cancer with adjuvant hormone therapy. ProSense® is already cleared for use in the US for treating benign tumors of the breast, and tumors in the kidney and liver.
The company’s ICE3 study evaluated the use of IceCure’s minimally invasive 20-to-40-minute outpatient cryoablation procedure for the treatment of low-risk, early-stage malignant breast tumors. The 5-year recurrence-free rates from the study were in line with expectations and show similar outcomes to lumpectomy, the current standard of care for early-stage breast cancer patients.
“We believe ICE3 is a ground-breaking study and are excited to report that the efficacy data of our minimally invasive ProSense® cryoablation procedure show similar outcomes in recurrence compared to more invasive breast surgery, the current standard of care for early-stage breast cancer."
IceCure CEO, Eyal Shamir
The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them.
IceCure says that initial reimbursement codes are already in place and its US marketing and commercial team expects rapid adoption of the technology. ProSense® was granted Breakthrough Designation by the FDA in 2021.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
IceCure Medical (Nasdaq: ICCM) is featured on PRISM Emerging MedDevices Index
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)